Product comparison studies

Mean hourly percent reduction from baseline in MSC severity scores

• _{REACTINE® 10 mg [dotted line]}

• _{Loratadine 10 mg [square line]}

• _{Placebo [triangle line]}

_{Results from an environmental exposure unit study
Reprinted with permission from Elsevier.
MSC = Major Symptom Complex. QD = once daily. †P≤0.05, ‡P≤0.01 vs placebo. §P≤0.05, ॥P≤0.01 vs loratadine.  
Adapted from Day, et al.}  

Footnotes

_{*Results from a 2-day, randomized, double-blind, parallel-group study where eligible patients were randomized to receive 10 mg once daily REACTINE® (n=67), 10 mg once daily loratadine (n=67) or placebo (n=68). Symptoms were assessed by the patients during two 6-hour periods of controlled exposure to ragweed pollen.}  

_{¶The primary endpoints were the total symptom complex (TSC) and the major symptom complex (MSC) scores. MSC symptoms included runny nose, sniffles, itchy nose, nose blows, sneezes, and watery eyes.} 

_{The environmental exposure unit (EEU) is a modified room used to expose large groups of subjects to uniform concentrations of ragweed pollen for periods up to 14 hours. In this study, the pollen concentration was comparable to that found in some environments during peak ragweed season.}   

References

^{1. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101(5):638-645. Doi: 10.1016/S0091-6749(98)70172-1}